These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32448790)

  • 1. 10-Valent pneumococcal non-typeable
    Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
    BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
    Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
    Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
    Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS
    BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
    Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
    Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal
    Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Licciardi P; Skull S; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
    Vaccine X; 2021 Apr; 7():100086. PubMed ID: 33681756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
    Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield M; Lehmann D; Binks MJ; Licciardi PV; Andrews R; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
    Int J Pediatr Otorhinolaryngol; 2023 Dec; 175():111776. PubMed ID: 37951020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.
    Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; Brown NJ; McIntyre P; Smith-Vaughan H; Skull S; Balloch A; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
    BMJ Open; 2015 Jan; 5(1):e007247. PubMed ID: 25596202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
    Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
    Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
    PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland K; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield MD; Lehmann D; Brennan-Jones CG; Binks MJ; Licciardi PV; Andrews RM; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
    PLoS Med; 2024 Jun; 21(6):e1004375. PubMed ID: 38829821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.